Treatment of the genitourinary syndrome of menopause.

S Palacios, A Mejía, J L Neyro

Journal: Climacteric : the journal of the International Menopause Society 2016;18 Suppl 1():23-9

PMID: 26366797

Abstract

The vagina, vulva, vestibule, labia majora/minora, and bladder trigone have a high concentration of estrogen receptors; therefore, they are a sensitive biological indicator of serum levels of these hormones in women. The estrogen loss in postmenopausal women produces a dysfunction called genitourinary syndrome of menopause. The principal therapeutic goal in the genitourinary syndrome of menopause is to relieve symptoms. Treatment options, as well as local and systemic hormonal treatment are changes in lifestyle and non-hormonal treatments mainly based on the use of moisturizers and lubricants. New treatments that have recently appeared are ospemifeme, the first selective hormone receptor modulator for dyspareunia and vulvovaginal atrophy treatment, and the use of vaginal laser. This review has been written with the intention of giving recommendations on the prevention and treatment of genitourinary syndrome of menopause.

Address: a Palacios Institute of Women´s Health , Madrid , Spain.; b * Hospital Universitario de Cruces , Bilbao , Spain.

DOI: 10.3109/13697137.2015.1079100

Link outs

Free resources

Medical:

https://medlineplus.gov/menopause.html

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-BRIP1-5

Subscription / membership required

Full Text Sources:

https://www.tandfonline.com/doi/10.3109/13697137.2...

MeSH Terms: Androgens, Atrophy, Dyspareunia, Estrogen Replacement Therapy, Estrogens, Female, Female Urogenital Diseases, Humans, Laser Therapy, Life Style, Lubricants, Menopause, Postmenopause, Selective Estrogen Receptor Modulators, Syndrome, Tamoxifen, Vagina, Vulva, Women's Health